• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

No interaction between race and aspirin dose for the secondary prevention of cardiovascular disease

byPaary BalakumarandAlex Chan
August 15, 2024
in Cardiology, Chronic Disease, Hematology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In patients with an established history of atherosclerotic cardiovascular disease (ASCVD) randomized to either take a daily high (325mg) or low (81mg) dose aspirin, there was no interaction between race and the primary endpoint consisting of death, hospitalization for myocardial infarction, or stroke. 

Evidence Rating Level: 1 (Excellent) 

In the USA, there are disparities in the outcome of atherosclerotic cardiovascular disease (ASCVD) between Black and non-Black patients. This disparity is due to many factors, one of which may be the different reactions of platelets in self-reported Black patients to aspirin. Aspirin prevents clinical events in patients with ASCVD and is a recommended option for secondary prevention of cardiovascular events. However, no study has looked at the dose-dependent effect of aspirin on Black patients. The ADAPTABLE randomized controlled trial compared the effects of two different doses of aspirin (81mg or 325mg daily) on clinical outcomes of 15 076 patients in the USA. This study used ADAPTABLE to evaluate the dose-dependent effect of aspirin. The primary endpoint was a composite of death from any cause, hospitalization for myocardial infarction, or stroke. Secondary endpoints included coronary revascularization or coronary artery bypass graft. The primary safety endpoint was a hospitalization for bleeding requiring transfusion. Over the 26.2 months median follow-up, the primary effectiveness endpoint was significantly higher in Black and other participants relative to White participants (overall p value < 0.001). The dosage of aspirin did not affect primary effectiveness endpoint (p = 0.12), primary safety endpoint (p = 0.46), or secondary effectiveness endpoint. 

Click to read the study in PLOSONE

Image: PD

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc. 

RELATED REPORTS

An absence of cardiovascular risk factors is linked to over ten additional healthy years

2 Minute Medicine Rewind September 1, 2025

Significant body weight reduction with cagrilintide-semaglutide therapy

Tags: ascvdaspirincardiologycvdthrombosis
Previous Post

Early intensive glycemic control reduces long-term risk of death and myocardial infarction in patients with type 2 diabetes

Next Post

#VisualAbstract: Belantamab Mafodotin in Combination with Standard-Care Therapies Improved Progression-Free Survival in Patients with Multiple Myeloma Compared to Standard-Therapy Alone

RelatedReports

Cardiology

An absence of cardiovascular risk factors is linked to over ten additional healthy years

September 2, 2025
Imatinib safe and effective as long-term treatment for chronic myeloid leukemia: The IRIS trial
Weekly Rewinds

2 Minute Medicine Rewind September 1, 2025

September 1, 2025
Cardiology

Significant body weight reduction with cagrilintide-semaglutide therapy

August 29, 2025
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Cardiology

Catheter ablation improves cardiovascular prognosis in patients with atrial fibrillation compared to drug therapy

August 27, 2025
Next Post
#VisualAbstract: Belantamab Mafodotin in Combination with Standard-Care Therapies Improved Progression-Free Survival in Patients with Multiple Myeloma Compared to Standard-Therapy Alone

#VisualAbstract: Belantamab Mafodotin in Combination with Standard-Care Therapies Improved Progression-Free Survival in Patients with Multiple Myeloma Compared to Standard-Therapy Alone

Intrapartum serum prolactin may predict risk of postpartum diabetes

Biguanides and dipeptidyl peptidase-4 inhibitors use have similar outcomes for diabetic patients

2 Minute Medicine Rewind August 19, 2024

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Computed Tomographic Angiography and Yield for Gastrointestinal Bleeding in the Emergency Department
  • Novo’s self replicating RNA push expands cardiometabolic pipeline
  • Long-term Outcomes of Patients with Crohn’s Disease Treated with Risankizumab
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.